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Epstein-Barr virus (EBV) is a ubiquitous human 
γ-herpesvirus implicated in the pathogenesis of 
several malignancies of lymphoid and epithelial 
origin (1–3). Primary infection with EBV usu-
ally occurs within the fi  rst three years of life by 
parent-to-child oral transmission in an almost 
always asymptomatic fashion. Delayed primary 
infection in adolescence or adulthood may cause 
the syndrome of infectious mononucleosis (4). 
After oral transmission, the virus replicates in 
the oropharynx from where it colonizes the 
host by latently infecting B cells. The tropism 
for B cells is at least partly a refl  ection of the B 
cell lineage–specifi   c, high level expression of 
the principal EBV receptor CD21, which is the 
ligand for the outer membrane glycoprotein 
BLLF1, also referred to as gp350/220 (5). In in-
fected B cells, EBV is able to establish diff  erent 
types of latency based on the set of viral genes 
expressed. During the primary phase of B cell 
infection, as well as in lymphoblastoid cell lines 
(LCL) generated by infection of B cells with 
EBV in vitro, the full range of nine viral latent 
proteins is expressed and these drive the activa-
tion and proliferation of the infected B cell. 
After immune control of primary infection, the 
numbers of infected B cells fall and the pattern 
of EBV latency changes. Expression of most, if 
not all, latent proteins is down-regulated, al-
lowing EBV to evade immune recognition and 
elimination and to persist in the memory B cell 
compartment for life (6). As yet poorly defi  ned 
signals may cause reactivation of EBV after ter-
minal diff  erentiation of the infected cells into 
plasma cells, followed by virus production and 
reinfection of B cells (7, 8).
The critical importance of the immune sys-
tem in controlling primary and persistent EBV 
infection is highlighted by the frequency and 
severity of EBV-associated disease in immuno-
com  promised individuals. The development of 
EBV-    positive posttransplant lymphoproliferative 
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Epstein-Barr virus (EBV) establishes lifelong persistent infections in humans by latently 
infecting B cells, with occasional cycles of reactivation, virus production, and reinfection. 
Protective immunity against EBV is mediated by T cells, but the role of EBV-specifi  c T 
helper (Th) cells is still poorly defi  ned. Here, we study the Th response to the EBV lytic 
cycle proteins BLLF1 (gp350/220), BALF4 (gp110), and BZLF1 and show that glycoprotein-
specifi  c Th cells recognize EBV-positive cells directly; surprisingly, a much higher percent-
age of target cells than those expressing lytic cycle proteins were recognized. Antigen is 
effi  ciently transferred to bystander B cells by receptor-mediated uptake of released virions, 
resulting in recognition of target cells incubated with <1 virion/cell. T cell recognition 
does not require productive infection and occurs early after virus entry before latency is 
established. Glycoprotein-specifi  c Th cells are cytolytic and inhibit proliferation of lympho-
blastoid cell lines (LCL) and the outgrowth of LCL after infection of primary B cells with 
EBV. These results establish a novel role for glycoprotein-specifi  c Th cells in the control of 
EBV infection and identify virion proteins as important immune targets. These fi  ndings have 
implications for the treatment of diseases associated with EBV and potentially other coated 
viruses infecting MHC class II–positive cells.
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disorders (PTLDs) in immunosuppressed bone marrow and 
solid organ transplant recipients and the successful treatment 
of such lymphomas by the infusion of EBV-specifi  c T cell 
lines generated by repeated stimulation of peripheral blood 
T lymphocytes with autologous LCL in vitro have established 
T cells as critical immune eff  ector cells in EBV immunity 
(1, 9). The polyclonal LCL-stimulated T cell preparations used 
to treat PTLDs contain CD4+ as well as CD8+ components, 
and both components may be necessary for the clinical eff  ec-
tiveness of this adoptive T cell therapy (10). Although the tar-
gets of the EBV-specifi  c CD8+ cytotoxic T cell response have 
been studied in detail, the CD4+ Th cell response to EBV 
remained ill defi  ned (11). In recent years, the search for the 
targets of the EBV-specifi  c Th response has gained momen-
tum after observations underlining the importance of CD4+ 
T cells in the initiation and maintenance of adaptive immune 
responses to viruses (12) and tumors (13). Although Th re-
sponses to some latent antigens of EBV have been   described, 
information on the Th immune response to lytic antigens of 
EBV is still scarce (11). During lytic replication, a large array 
of >80 EBV proteins is expressed and exposed to the im-
mune system (8). However, EBV has evolved mechanisms by 
which lytically infected cells can evade immune recognition, 
including down-regulation of MHC class I and II molecules, 
and secretion of gp42, a glycoprotein interfering with antigen 
recognition by CD4+ T helper cells (14, 15). Thus, although 
Th responses to the lytic cycle proteins BZLF1, BMRF1, 
BHRF1, and BLLF1 have been described, and T cells specifi  c 
for the latter two antigens have been isolated from latently 
infected donors, it is still largely unknown which lytic cycle 
proteins of EBV elicit T helper responses, which are the dom-
inant targets of the EBV-specifi  c T helper response, and how 
Th cells specifi  c for lytic cycle antigens contribute to EBV 
immunity (16–18).
In the infected host, the reservoir of latently infected 
memory B cells can seed foci of virus replication at mucosal 
sites, and this reactivation of the virus and subsequent rein-
fection of B lymphocytes that reenter the periphery has been 
suggested to contribute to the maintenance of persistence 
(19). Thus, immune responses directed against lytic antigens 
may aid at controlling persistent infection by preventing a 
recrudescence of viremia associated with this cyclic pattern of 
transmission between compartments and, in addition, by pre-
venting the host from superinfection with further strains of 
orally transmitted virus. Circumstantial evidence in support 
of this scenario has been provided by studies demonstrating 
that healthy virus carriers are consistently positive for IgG 
antibodies to lytic antigens of EBV (1). Because Ig isotype 
switching requires cognate T cell help (20), the presence of 
IgG antibodies to lytic cycle antigens implies that these anti-
gens are also targets of the CD4+ Th cell response. Moreover, 
healthy virus carriers maintain CTL memory to lytic cycle 
epitopes during the persistent phase of infection, and the fre-
quencies of these T cells often exceed those seen for CTL 
memory to latent cycle epitopes (21). Such lifelong CTL and 
antibody responses are probably a refl  ection of continuous 
antigenic stimulation after virus reactivation and replication. 
Here, we sought to examine the T helper cell   response to 
lytic antigens of EBV and to assess the role of these T cells in 
establishing protective immunity against EBV.
RESULTS
Generation of EBV lytic cycle antigen-specifi  c T helper cell 
lines from a healthy virus carrier
To study the Th cell immune response against lytic antigens 
of EBV, we sought to isolate and characterize Th cells spe-
cifi  c for the lytic cycle proteins BZLF1, BALF4, and BLLF1 
from peripheral blood of a healthy virus carrier. BZLF1 and 
BLLF1 were chosen because Th responses against these anti-
gens had been detected in peripheral blood of patients with 
infectious mononucleosis and healthy virus carriers, respec-
tively (16, 18). In addition, the glycoprotein BALF4 (also 
referred to as gp110) was included in this analysis because hu-
moral but no Th cell responses against this antigen have been 
described (22). BZLF1, BLLF1, and BALF4 proteins were 
expressed and purifi  ed as histidine-tagged proteins from Sf9 
insect cells infected with recombinant baculoviruses. PBMCs 
from the healthy EBV-infected donor JM were pulsed with 
the recombinant proteins and used to stimulate autologous 
CD4+ T cells. After several rounds of stimulation, the CD4+ 
T cell lines specifi  cally responded against the protein used for 
stimulation, but not against control proteins (Fig. 1). These 
results indicated that CD4+ T cell memory to lytic antigens 
does exist and can be reactivated from peripheral blood of 
healthy virus carriers with this approach in vitro.
Characterization of the lytic antigen-specifi  c CD4+ T cells
For the purpose of characterizing these T cells in more 
detail, we cloned the CD4+ T cell lines by limiting dilution. 
Figure 1.  CD4+ T cell memory to lytic cycle proteins of EBV in the 
peripheral blood of healthy virus carriers. 106/ml PBMCs from the 
latently EBV-infected donor JM were incubated in separate wells with 
purifi  ed recombinant BLLF1, BZLF1, and BALF4 proteins, and then used to 
stimulate autologous CD4+ T cells from peripheral blood. The specifi  city 
of the T cell lines was assayed by GM-CSF ELISA. After six rounds of 
stimulation (p6), the lines began to show reactivity to PBMCs pulsed with 
the stimulator protein, but not against control proteins.JEM VOL. 203, April 17, 2006  997
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Antigen-specifi  c CD4+, CD8−, TCRα/β+, and TCRγ/δ-
negative T cell clones were obtained from all three T cell 
lines (unpublished data). Clonality of the single cell out-
growths was verifi  ed by RT-PCR analysis in conjunction 
with Southern blot hybridization of the variable part of the 
T cell receptor β chain (TCR-Vβ). The various antigen-
specifi  c T cell clones established from each antigen-specifi  c 
line expressed at least two diff  erent Vβ chains, indicating that 
they derived from diff  erent precursors. The restricting MHC 
molecules were identifi  ed by testing the T cells against anti-
gen-pulsed PBMCs from various donors sharing diff  erent 
MHC class II alleles with donor JM. The epitopes recognized 
by the T cells were identifi  ed using the DEPI method (23). T 
cell clones expressing the same Vβ chain recognized the same 
epitope presented on the same MHC II molecule. Six repre-
sentative clones specifi  c for two diff  erent epitopes in each of 
the three antigens were chosen for further analysis (Table I).
To defi  ne the affi   nities of the T cells for their cognate an-
tigen, peptides spanning the epitopes were synthesized, pulsed 
at various concentrations onto autologous PBMCs, and rec-
ognition by the T cell clones was assayed in cytokine secre-
tion experiments. As shown in Fig. 2, the various clones 
recognized target cells pulsed with 1–3 nM of the cognate 
peptide, whereas responses to control peptides were not ob-
served even at much higher concentrations. Along with GM-
CSF, all clones secreted IFN-γ in response to antigenic 
stimulation, suggesting that they are of Th1 subtype.
Recognition of EBV-positive target cells by the lytic 
antigen-specifi  c T cells
When tested against LCL, some T cells even responded 
against target cells that had not been pulsed with the cognate 
peptide or protein. This was unexpected because only a small 
proportion of cells within an LCL culture spontaneously 
become permissive for lytic replication (8). However, not all 
T cells were able to recognize EBV-positive target cells. 
Although BALF4- and BLLF1-specifi  c T cell clones recog-
nized autologous and HLA-matched LCL (Fig. 3 A) as well 
as type I and type III EBV-positive Burkitt’s lymphoma (BL) 
cell lines (Fig. 3 B), BZLF1-specifi  c T cell clones failed to 
recognize EBV-positive targets. To investigate antigen 
  expression, processing, and presentation in more detail, we 
took advantage of a genetically engineered EBV strain called 
miniEBV. This virus mutant is still able to infect and trans-
form B cells into so-called miniLCL, but is unable to enter 
the lytic cycle (24, 25). Although miniLCL are identical to 
LCL generated by infection of B cells with B95.8 virus in 
terms of antigen presentation and T cell costimulation (24), 
miniLCL established from donor JM were not recognized by 
the BALF4- and BLLF1-specifi  c T cell clones and neither were 
miniLCL counterparts of HLA-matched allogeneic LCL that 
were recognized by the T cells (Fig. 3 C).
Transfer of antigen occurs between cells in culture
The diff  erence in the recognition of LCL and miniLCL by 
the T cells suggested that the glycoprotein-specifi  c T cells 
recognize EBV-positive target cells undergoing lytic replica-
tion. However, the strong response to LCL by the T cell 
clones in cytokine secretion assays was unexpected consider-
ing the low percentage of cells that spontaneously become 
permissive for viral replication (8). Immunofl  uorescence 
staining of LCL with BZLF1- and BLLF1-specifi  c monoclo-
nal antibodies demonstrated that <1% of cells had entered 
the lytic cycle, whereas no staining was seen with miniLCL 
Figure 2.  Affi  nity of the T cell clones for their cognate antigen. 
Peptides at various concentrations were pulsed onto autologous PBMCs 
for 2 h at 37°C. Subsequently the cells were irradiated (40Gy), unbound 
peptide was removed by extensive washing, and the cells were used as 
stimulators for the T cells. IFN-γ secretion by the T cells was measured 
24 h later by ELISA. As shown for three T cell clones, all T cells described in 
this work recognized their cognate peptide (closed symbols) at a mini-
mum concentration of 1–3 nM, whereas no response against PBMCs 
pulsed with an irrelevant peptide (open symbols) was observed.
Table I.  Characterization of the CD4+ T cell clones specifi  c for BLLF1, BALF4, and BZLF1
T cell clone Epitope Restriction TCR-V𝗃
BLLF1-1H2 BLLF1 AA130–144 -V  Y  F  Q  D  V  F  G  T  M  W  C  H  H  A  - HLA-DQB1*0402 Vβ5.2
BLLF1-1D6 BLLF1 AA65–79  -F  G  Q  L  T  P  H  T  K  A  V  Y  Q  P  R  - HLA-DRB1*1301 Vβ21
BZLF1-3E4 BZLF1 AA207–221   -K  S  S  E  N  D  R  L  R  L  L  L  K  Q  M  - HLA-DQB1*0402 Vβ21
BZLF1-3H11 BZLF1 AA174–188 -E  L  E  I  K  R  Y  K  N  R  V  A  S  R  K  - HLA-DRB1*1301 Vβ4
BALF4-B5 BALF4 AA482–496  -A  W  C  L  E  Q  K  R  Q  N  M  V  L  R  E  - HLA-DPB1*1301 Vβ6
BALF4-A9 BALF4 AA575–589  -D  N  E  I  F  L  T  K  K  M  T  E  V  C  Q  - HLA-DRB1*0801 Vβ19
Six T cell clones recognizing two different epitopes in each of the three antigens were further characterized. The amino acid sequences and positions of the epitopes within 
the EBV B95.8 protein sequence are given, together with the restricting MHC molecules and the Vβ chains (TCR-Vβ) expressed by the different T cell clones.998  T HELPER CELL RESPONSE TO EPSTEIN-BARR VIRUS | Adhikary et al.
(unpublished data). Furthermore, cells undergoing lytic rep-
lication are known to down-regulate expression of MHC 
molecules and to secrete gp42, an EBV glycoprotein that in-
hibits T helper cell recognition (14, 15). To assess the per-
centage of cells in LCL cultures that were recognized by the 
T cells, we assayed a fi  xed number of antigen-specifi  c T cells 
with serial dilutions of autologous LCL, miniLCL, or MHC-
mismatched LCL by IFN-γ ELISPOT. As shown in Fig. 4 A, 
a surprising 20% of the cells in an LCL culture were recog-
nized by glycoprotein-specifi  c T cells. Wells containing 
miniLCL or MHC-mismatched LCL showed background 
number of spots. No spots above background were detected 
with BZLF1-specifi  c T cells, irrespective of the target cells 
used (unpublished data).
The discrepancy in the number of cells positive for 
BLLF1 in immunofl  uorescence studies and the number of 
cells positive in the ELISPOT experiments suggested that 
antigen is transferred between cells. To address this possi-
bility, we performed cell-mixing experiments. Autologous 
miniLCL were cocultured with MHC-mismatched alloge-
neic LCL for various periods of time and then probed with 
the lytic antigen-specifi  c T cells. Although none of the 
lines was recognized alone, the cell mix was recognized by 
the glycoprotein-specifi  c, but not BZLF1-specifi  c, T cell 
clones (Fig. 4 B).
Potential sources of the transferred antigens were either 
fragments of cells in which EBV had replicated or released vi-
rus particles. To test the latter possibility, we purifi  ed virus 
from supernatant of the B95.8 marmoset cell line, pulsed it 
onto miniLCL, and subsequently probed the cells with the 
T cells. The virus-pulsed target cells were recognized by the 
BLLF1- and BALF4-specifi  c T cells, demonstrating that viral 
particles are capable of transferring antigen. To investigate 
whether antigen was transferred directly in the form of viral 
proteins in the virions or indirectly by superinfecting mini-
LCL, heat-inactivated virus supernatant incapable of immor-
talizing primary B cells in control experiments was pulsed 
onto miniLCL. As shown in Fig. 4 C, heat inactivation of the 
virus supernatant did not aff  ect T cell recognition. Moreover, 
T cell recognition occurred already 12 h after incubation of 
miniLCL with purifi  ed virus or coculture with allogeneic LCL. 
This excluded superinfection of miniLCL as the mechanism of 
Figure 3.  Recognition of EBV-positive target cells by lytic antigen-
specifi  c T cells. (A) Autologous LCL, allogeneic LCL sharing distinct 
MHC II alleles with donor JM (MA: DR8, DQ4; LA: DQ6, DP13; GB: 
DR13, DQ6, DP4), and MHC II–mismatched LCL (SM, DA) were cocul-
tured with the T cell clones specific for lytic antigens for 24 h. Subse-
quently, IFN-γ secretion by T cells was measured by ELISA. T cells 
specific for the glycoproteins BALF4 and BLLF1, but not the immediate 
early protein BZLF1, recognized autologous and MHC II–matched LCL. 
Autologous PBMCs pulsed with the specific protein were used as 
specificity control and T cells were cultivated without target cells 
(T alone) were included as controls to detect nonspecific secretion of 
cytokines by the T cells. (B) The glycoprotein-specific T cells recog-
nized EBV-positive BL cell lines expressing the restriction element of 
the T cell clones (Ag876: DP13; BL30: DR13; BL60: DQ4). BL30-B95.8 is 
an EBV-positive convertant of the parental, EBV-negative BL30 cell 
line. (C) The glycoprotein-specific T cells failed to recognize miniLCL 
generated by infection of B cells with an EBV mutant unable to enter 
the lytic cycle.JEM VOL. 203, April 17, 2006  999
ARTICLE
antigen transfer because expression of glycoproteins after induc-
tion of lytic replication requires 48–72 h (8). Instead, these re-
sults indicated that virus particles can function as a passive vector 
for the transfer of immunogenic viral structural proteins.
B cells are the major antigen-presenting cells 
for virion proteins
The effi   cient recognition of miniLCL cocultured with alloge-
neic LCL was surprising because LCL supernatant is known to 
contain few infectious virus particles. Infection of B lympho-
cytes by EBV is receptor mediated and involves adsorption of 
BLLF1 to CD21, followed by aggregation of CD21 on the 
plasma membrane and the internalization of EBV into cytoplas-
mic vesicles (5, 26). To test whether this receptor-mediated up-
take of EBV is essential for the antigen transfer by virions, the 
EBV supernatant was incubated with the anti-BLLF1 monoclo-
nal antibody 72A1 and added to miniLCL. In parallel, miniLCL 
were incubated with the anti-CD21 monoclonal antibody FE8 
before addition of the viral supernatant. Both antibodies had 
been shown to prevent EBV infection of B cells (27, 28). Treat-
ment with these, but not with isotype control antibodies, com-
pletely abrogated T cell recognition, suggesting that the transfer 
of virion antigens is dependent on receptor-mediated virus 
uptake (Fig. 5 A). To test whether only APC-expressing CD21 
were able to present virion antigens on MHC class II, we pulsed 
EBV supernatant onto autologous miniLCL, monocyte-derived 
DCs, and PBMCs. As shown in Fig. 5 B, miniLCL and PBMCs, 
but not DCs, were able to present virion antigens to T cells 
when incubated with purifi  ed virus supernatant. Of note, DCs 
effi   ciently stimulated the T cells when pulsed with BLLF1 pep-
tides and, importantly, when incubated with   purifi  ed BLLF1 
protein, demonstrating that uptake, processing, and presentation 
of exogenous antigens was not impaired in these cells. In fact, of 
all cell types tested, DCs presented   exogenous antigens most 
effi   ciently on MHC class II (Fig. 5 C). Within PBMCs, the 
CD19-positive but not the CD19-  negative population was able 
Figure 4.  Antigen is transferred from lytically infected B cells to 
bystander B cells by virions. (A) Different numbers of autologous LCL, 
miniLCL, and MHC II–mismatched LCL were incubated with 105/well 
BLLF1-1H2 T cells. The number of target cells recognized by the T cells 
was determined by IFN-γ ELISPOT and are depicted as spot-forming cells 
(SFC). Approximately 20% of the autologous LCL were detected by the 
T cells, whereas miniLCL and MHC II–mismatched LCL gave background 
numbers of spots. (B) MiniLCL JM were cocultured with MHC II–
  mismatched LCL DA or miniLCL DA for 24 h and probed with lytic 
 antigen-specifi  c T cells. MiniLCL JM cocultured with LCL DA, but not mini-
LCL DA, were recognized by glycoprotein-specifi  c, but not BZLF1-specifi  c, 
T cells. MiniLCL JM incubated with the cognate antigen were included as 
specifi  city control. (C) MiniLCL JM were cocultured with allogeneic LCL or 
incubated with heat-inactivated purifi  ed virus (hi-EBV) supernatant for 
different periods of time up to 120 h. Subsequently, the cells were fi  xed 
with paraformaldehyde and probed with BLLF1- and BALF4-specifi  c 
T cells. 12 h of coculture or incubation with heat-inactivated virus was 
suffi  cient for T cell recognition.1000  T HELPER CELL RESPONSE TO EPSTEIN-BARR VIRUS | Adhikary et al.
to stimulate the glycoprotein-specifi  c T cells, suggesting that the 
B cell fraction presented the virion-derived antigens (Fig. 5 D). 
To assess effi   ciency of this receptor-mediated antigen presenta-
tion, we determined the concentration of EBV genome equiva-
lent (geq) in the viral supernatant, pulsed increasing amounts of 
geq onto miniLCL, and subsequently assessed T cell recogni-
tion. MiniLCL incubated with as little as 0.8 geq per cell were 
recognized by BLLF1- and BALF4-specifi  c T cells, demonstrat-
ing that this receptor mediated uptake and that subsequent 
  presentation of virion antigens is extremely effi   cient (Fig. 5 E). 
When target cells were treated with chloroquine or leupeptin 
during incubation with viral supernatant, T cell recognition was 
almost completely abrogated, indicating that antigen processing 
  occurred in the lysosomal compartment (Fig. 5 F).
No detectable transfer of antigen from cell fragments 
and released proteins
These experiments illustrated that receptor-mediated uptake 
of virions plays a central role in the transfer of antigen, but 
did not exclude that proteins released by lysed cells contrib-
uted to this process. The failure of T cells specifi  c for the 
transcription factor BZLF1 to recognize LCL had suggested 
that the amount of antigen released by lysed cells is insuffi   -
cient for T cell stimulation. However, in lytically infected 
cells, the virion proteins BLLF1 and BALF4 are expressed at 
much higher levels than the transcription factor BZLF1 (8). 
Therefore, released virion proteins might reach levels suffi   -
cient for T cell detection. Because DCs were incapable of 
  receptor-mediated uptake of virion-derived antigens, we 
used DCs to assess to what extent released proteins and cell 
debris contributed to the transfer of antigen. Autologous DCs 
were cocultured with MHC-mismatched LCL and probed 
with the lytic antigen-specifi  c T cells. None of the T cell 
clones recognized the DCs, even after extended periods of 
coculture, demonstrating that cells debris or proteins released 
from lytically EBV-infected cells contributed insignifi  cantly, 
if at all, to the transfer of antigen (Fig. 6).
Glycoprotein-specifi  c CD4+ T cells are cytolytic 
and suppress the growth of EBV-infected cells
To assess direct eff   ector functions of the glycoprotein-
  specifi  c T cells on the growth of EBV-infected target cells, 
Figure 5.  Effi  cient presentation of virion-derived antigens 
after receptor-mediated uptake. (A) MiniLCL JM were incubated with 
the anti-CD21 antibody FE8 or an isotype control (Iso1) antibody and 
pulsed with virus supernatant (EBV). In parallel, virus supernatant was 
incubated with the anti-BLLF1 antibody 72A1 or an isotype control anti-
body (Iso2) and pulsed onto miniLCL. After 24 h of incubation, virus-
pulsed miniLCL were probed with the T cells. (B) MiniLCL, PBMCs, and 
dendritic cells (DC) were incubated with increasing amounts of purifi  ed 
virus for 24 h and probed with BLLF1-1H2 T cells. (C) The three types of 
APCs as in B were incubated with increasing amounts of purifi  ed BLLF1 
mutant protein lacking the CD21 binding domain for 24 h and 
  subsequently probed with the BLLF1-1H2 T cells. (D) PBMCs were sepa-
rated into CD19+ and CD19− cell fractions by magnetic sorting and sub-
sequently incubated for 24 h with increasing amounts of purifi  ed viral 
particles before addition of glycoprotein-specifi  c T cells. (E) MiniLCL were 
pulsed for 24 h with increasing amounts of EBV geq and probed with 
BLLF1- and BALF4-specifi  c T cells as indicated. (F) MiniLCL JM were incu-
bated for 24 h with   purifi  ed viral supernatant in the absence or presence 
of leupeptin or chloroquine. After the incubation period, unbound virus 
and inhibitors were removed by washing, and the cells were fi  xed and 
probed with the glycoprotein-specifi  c T cells.JEM VOL. 203, April 17, 2006  1001
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serial   dilutions of LCL and mini-LCL were plated with or 
without 10,000 monoclonal T cells, and proliferation of the 
cultures was followed over time. The GFP-specifi  c CD4+ 
T cell clone 3A2 (also established from donor JM) was in-
cluded as a control (29). After 4 wk, the cultures were assayed 
microscopically for the outgrowth of cells, and CD19 stain-
ing demonstrated that the outgrowing cells were exclusively 
B cells (unpublished data). As compared with irrelevant GFP-
specifi  c T cells, proliferation of LCL but not miniLCL was 
strongly impaired in the presence of glycoprotein-specifi  c 
T cells. Approximately sevenfold higher numbers of LCL 
were required to achieve continuous proliferation of the cells 
than in control wells (Fig. 7 A). The glycoprotein-specifi  c 
T cells BLLF1-1H2 also inhibited proliferation of the MHC 
II–matched EBV-positive type I BL cell line BL60. Approxi-
mately three- to fourfold more BL60 cells were required to 
obtain proliferating cultures than in the presence of GFP-3A2 
and BALF4-A9 T cells. Proliferation of miniLCL was not af-
fected by any of the T cells used (Fig. 7 A). These experi-
ments indicated that T cells specifi  c for virion proteins may 
play an important role in limiting virus spread by inhibiting 
or eliminating B cells that have become infected by EBV. To 
investigate whether glycoprotein-specifi  c T cells could limit 
the number of productively infected B cells and consequently 
the generation of LCL in vitro, B cells from donor JM were 
incubated with B95.8 virus for 4–24 h. Subsequently, the 
cells were washed to remove free virus and plated at various 
dilutions in 96-well microtiter plates together with 10,000 
BLLF1-, BALF4-, BZLF1-, or GFP-specifi  c T cells. Cul-
tures were maintained by weekly refeeding and assayed for 
LCL outgrowth after 4 wk. By that time, outgrowth was im-
mediately apparent from microscopic inspection of the wells, 
and CD19 staining confi  rmed that the outgrowing cells are 
of B cell origin and not surviving T cells. Fig. 7 B depicts 
the results of a representative experiment expressed as x-fold 
input cell number at which outgrowth of LCL occurred. 
Addition of the BLLF1- and BALF4-specifi  c T cells greatly 
diminished the number of wells with LCL outgrowth. Com-
pared with control wells to which BZLF1- or GFP-specifi  c 
T cells had been added,  10-fold higher numbers of EBV-
infected B cells were required to obtain LCL outgrowth. 
In accordance with the fi  nding that virus-pulsed B cells are able 
to present virion glycoproteins even beyond 120 h of pulsing, 
delaying the time of exposure of the virus-pulsed B cells to 
T cells did not aff  ect the outcome of the experiments. Addi-
tion of cyclosporin A to the cultures also did not abrogate this 
inhibition, indicating that cytokines secreted by the T cells 
were unlikely to mediate this eff  ect (unpublished data). To 
investigate whether the T cells were able to lyse target cells 
upon recognition, miniLCL pulsed with cognate or control 
peptides were incubated with the various T cells for 3 h. 
Subsequently, lysis of the target cells was measured in a euro-
pium release assay. Upon antigen recognition, glycoprotein-
  specifi  c T cells effi   ciently lysed target cells (Fig. 7 C). The 
T cells also secreted perforin and granzyme B in an antigen-
specifi  c manner, suggesting that cytolysis is mediated by the 
granule exocytosis pathway (Fig. 7, D and E).
Th cell responses to EBV glycoproteins are consistently 
detected in healthy virus carriers
If glycoprotein-specifi  c Th cells played an important role in 
the control of EBV infection in vivo, Th cell responses against 
these antigens should be detectable in a signifi  cant proportion 
of healthy virus carriers. The last set of experiments, there-
fore, sought to address whether Th cells specifi  c for BLLF1 
and BALF4 are detectable in peripheral blood of latently 
EBV-infected donors. Peripheral blood CD4+ T cells from 
four EBV-seropositive donors and one EBV-seronegative 
healthy adult were repeatedly stimulated using autologous 
PBMCs pulsed with recombinant BLLF1 and BALF4 pro-
teins. After fi  ve to seven rounds of stimulation, T cell lines 
from all four EBV-seropositive donors, but not from the 
EBV-seronegative donor, showed specifi  city for the antigen 
used for stimulation (Fig. 8). The successful isolation of 
BALF4- and BLLF1-specifi  c CD4+ Th cells from peripheral 
blood of all the healthy virus carriers identifi  es these proteins 
as important and common targets of the EBV-specifi  c CD4+ 
T cell response.
D  I  S  C  U  S  S  I  O  N 
Maintenance of EBV persistence has been suggested to in-
volve cycles of virus reactivation, production, and reinfection 
of B lymphocytes (19). Immune responses directed against 
lytic cycle proteins of EBV are sustained during persistent 
  infection and, as indicated by shifts in the virus–host balance 
in immunocompromised individuals, are likely to interfere 
with this cyclic pattern of transmission (1).
Here we studied the poorly defi  ned T helper response to 
lytic cycle proteins of EBV. Because cell systems in which 
EBV infection leads directly into a fully productive lytic 
  infection are lacking and because it is unknown which of the 
Figure 6.  The amount of antigen released from lytically infected 
cells is insuffi  cient for T cell recognition. MiniLCL JM (5 × 105/ml) 
and DC JM (5 × 105/ml) were cultured either alone or together with the 
MHC II–mismatched LCL DA (ratio 1:1) for 24 h. After the cocultures, the 
cells were probed with BLLF1-1H2 T cells and cytokine secretion deter-
mined 24 h later by ELISA. MiniLCL and DC pulsed with the cognate pro-
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>80 diff  erent EBV proteins expressed during lytic replication 
are dominant T helper cell targets, we studied the T helper 
  response against defi  ned lytic cycle proteins. BALF4, BLLF1, 
and BZLF1 were chosen as candidate targets because humoral 
and/or cellular immune responses against these antigens have 
been described previously (1, 16, 18, 21, 22). Although all 
T cell clones recognized their cognate peptides with similar 
avidity, only CD4+ T cells specifi   c for the glycoproteins 
BLLF1 and BALF4, but not for the transcription factor 
BZLF1, recognized autologous as well as HLA-matched allo-
geneic EBV-infected target cells. MiniLCL generated by in-
fection of B cells with a genetically engineered miniEBV 
strain incapable of entering the lytic cycle were not recog-
nized, implying that T cell recognition was dependent on 
sporadic lytic replication occurring in a low percentage of 
cells in culture. However, a substantially higher percentage of 
cells was recognized than those positive for lytic cycle proteins 
in immunofl   uorescence studies. Coculture experiments of 
HLA-mismatched LCL and HLA-matched miniLCL indi-
cated that antigen was transferred from one cell type to the 
other. We provide several lines of evidence that the antigen 
transferred was derived from released virions. First, miniLCL 
pulsed with purifi  ed virus preparations were recognized by 
the T cells, demonstrating that virions can serve as a source of 
antigen. Because miniLCL pulsed with heat-inactivated virus 
were still recognized, T cell recognition does not depend on 
productive infection of the target cells. Of note, virus super-
natant has been used before as source of antigen to reactivate 
Figure 7.  Glycoprotein-specifi  c CD4+ T cells are cytolytic and in-
hibit outgrowth and proliferation of LCL. (A) Decreasing numbers of 
LCL JM, miniLCL JM, or BL60 cells were either cultured alone or cocultured 
with BLLF1-1H2, BALF4-A9, BZLF1-3H11, or GFP-specifi  c 3A2 T cells 
(10,000/well). Proliferation of the cells was followed over time and the 
minimum number of cells proliferating was determined after 4 wk. Cocul-
ture of LCL and BL60 cells, but not miniLCL, with glycoprotein-specifi  c 
T cells increased the minimum number of cells necessary for proliferation 
3–10-fold. (B) Purifi  ed B cells were infected with EBV and increasing cell 
numbers plated together with BLLF1-, BALF4-, BZLF1-, or irrelevant GFP-
specifi  c T cells (10,000/well). The minimum number of EBV-infected B cells 
required for LCL outgrowth was  10-fold higher in the presence of gly-
coprotein-specifi  c T cells. (C) MiniLCL JM pulsed with the indicated pep-
tides were cocultured with the BALF4-B5 T cells at different effector to 
target ratios. Upon antigen recognition, the glycoprotein-specifi  c T cells 
effi  ciently lysed the target cells. (D) Serial dilutions of miniLCL JM pulsed 
with cognate or control peptides were cocultured with glycoprotein-
specifi  c T cells, and perforin secretion by the T cells was assayed by 
ELISPOT. (E) In addition to IFN-γ, all glycoprotein-specifi  c T cell clones also 
secreted granzyme B in response to target cell recognition.JEM VOL. 203, April 17, 2006  1003
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and expand BLLF1-specifi  c T cells. In fact, these were the 
fi  rst EBV-specifi  c Th cell clones isolated and characterized in 
vitro (18, 30). The authors showed that these T cells were 
able to recognize LCL presenting endogenous and exogenous 
antigen on MHC II, but further implications of such recogni-
tion in the control of EBV infection were not addressed. 
Second, antigen is most effi   ciently transferred to B cells and 
this transfer can be blocked by BLLF1- and CD21-specifi  c 
monoclonal antibodies (27, 28), implying that antigen uptake 
is receptor mediated. Importantly, this antibody treatment not 
only prevented subsequent recognition by BLLF1-specifi  c 
but also by BALF4-specifi  c T cells, further adding to the no-
tion that the antigens presented are derived from virions and 
not from released proteins. Third, the failure of BZLF1-spe-
cifi  c T cells to recognize LCL, and the failure of BALF4- and 
BLLF1-specifi  c T cells to recognize autologous DCs cocul-
tured with HLA-mismatched LCL demonstrated that the 
amount of antigen released by dead or dying cells is not suffi   -
cient for T cell detection. This fi   nding was unexpected 
because DCs have been shown to effi   ciently  stimulate 
EBV-specifi  c cellular immune responses upon coculture with 
freshly EBV-infected B cells or LCL (31, 32). Two possibili-
ties may account for these discrepant results. First, the study 
by Bickham et al. focused on T cell responses to latent cycle 
antigens, which are expressed in all and not just a small per-
centage of cells in an LCL culture. Therefore, the amount of 
lytic cycle proteins available for uptake by DCs may be gener-
ally lower. This is especially true for BLLF1 and BALF4. 
These proteins are incorporated into virions that, as we have 
shown, are effi   ciently taken up by neighboring B cells but not 
by DCs. Second, we cocultured DCs with LCL for only 24 h, 
whereas in the study by Bickham et al. the cells were cocul-
tured for several days.   Recently, the lytic cycle protein 
BHRF1 has been shown to be transferred from lytically to 
  latently infected cells. Interestingly, 30 d of coculture were 
required to reach levels suffi   cient for T cell recognition (17). 
Therefore, effi     cient presentation of proteins released from 
LCL by DCs may require coculturing over several days.
The observation that mainly B cells, whether primary or 
EBV-infected, present virion proteins most effi   ciently impli-
cated a protective role of such T cells in controlling the spread 
of infection. Importantly, glycoprotein-specifi  c T cells recog-
nize target cells pulsed with virus supernatant before the EBV 
genome has circularized and before EBNA2, the protein es-
sential for primary B lymphocyte growth transformation, is 
expressed (33). EBV infection of B lymphocytes is initiated by 
BLLF1 adsorption to CD21 on the B cell plasma membrane, 
followed by BXLF2-mediated envelope fusion with the cell 
membrane and nucleocapsid exocytosis into the cytoplasm (5, 
26). During this process of virus uncoating, proteins of the 
  viral envelope are probably retained at the cell membrane, as 
indicated by the higher percentage of cells positive for BLLF1 
than for BZLF1 in immunofl   uorescence experiments (30). 
Because cell membrane proteins effi   ciently access the MHC 
class II processing and loading compartment, T helper cells 
specifi  c for envelope antigens are able to detect EBV-infected 
cells before viral latency is established. This   receptor-mediated 
virion uptake and subsequent presentation of glycoprotein-
derived peptides on MHC class II is extremely effi   cient. 
BALF4- and BLLF1-specifi  c T cells were able to recognize 
miniLCL incubated with less than one EBV geq per cell. 
Thus, virion proteins retained at the cell surface during virus 
uncoating render newly EBV-infected B cells vulnerable to 
immune attack by Th cells specifi   c for virion proteins. 
  Preliminary results with Th cells specifi  c for additional glyco-
proteins of EBV also   recognizing newly infected B cells 
  provide further evidence in support of this concept (unpub-
lished data). This mechanism of immune surveillance may not 
be limited to EBV, but may also apply to other coated viruses 
infecting MHC class II–positive target cells.
The glycoprotein-specifi  c CD4+ T cells described here 
are of Th1 type and cytolytic, and are able to inhibit the 
proliferation of EBV-positive BL cells as well as LCL in 
vitro. Importantly, these T cells are also able to prevent the 
outgrowth of primary B cells infected with EBV in vitro, 
implicating a role of such T cells in diminishing the pool 
of EBV-infected B cells in vivo. This notion is further sup-
ported by the successful isolation of T helper cells specifi  c 
for BLLF1 and BALF4 from peripheral blood of fi  ve out of 
fi  ve latently infected healthy virus carriers. Consistent with 
this, subsidence of T cell surveillance after immunosuppres-
sion is often associated with increased viral shedding in the 
throat, and higher numbers of EBV-infected B cells in the 
peripheral blood (34, 35). In bone marrow and solid organ 
transplant recipients, PTLD incidence correlates with sever-
ity of immunosuppression. In PTLDs as well as in Burkitt’s 
lymphoma, lytic replication has been observed at the site of 
tumor development (36, 37). Thus, glycoprotein-specifi  c 
Th cells may not only aid in controlling persistent infection, 
but may also play a role in the immune control of EBV-
  associated malignancies.
Figure 8.  Healthy virus carriers are consistently positive for glyco-
protein-specifi  c CD4+ T cells. CD4+ T cells from peripheral blood of 
one EBV-seronegative (EBV−) and four EBV-seropositive (EBV+) healthy 
donors were repeatedly stimulated with protein-pulsed autologous 
PBMCs. After fi  ve to seven restimulations, the T cell lines from all healthy 
virus carriers, but not from the EBV-negative control donor, specifi  cally 
responded against PBMCs pulsed with the protein used for stimulation.1004  T HELPER CELL RESPONSE TO EPSTEIN-BARR VIRUS | Adhikary et al.
As compared with blood or LCL cultures, diff  usion is 
  impeded in solid tumors leading to the sequestration and 
accumulation of viral progeny within tumors. Because the 
transformed cells in PTLDs are considered to be in vivo 
  correlates of LCL, these cells are expected to take up 
released virions with similar effi   ciency. Also, BL cells ex-
press the principal EBV receptor CD21 and have retained 
the ability to process exogenous antigen through the HLA 
class II pathway for presentation to CD4+ T cells (38). Be-
cause MHC class I antigen presentation is severely impaired 
in BL (39), CD4+ T cells may play an important role in the 
immune   response against this tumor. EBNA1-specifi  c Th1 
type CD4+ T cells have been shown to kill BL cells (40). 
However, because EBNA1 is the only EBV latent cycle an-
tigen expressed in BL and the recognition of endogenous 
antigen by EBNA1-specifi  c CD4+ T cells appears to diff  er 
between diff  erent    epitope specifi  cities,  glycoprotein-spe-
cifi  c Th cells, which we have found to recognize EBV-pos-
itive BL cell lines, may play a critical role in the immune 
response against this tumor.   Evidence in support of this 
concept has been obtained in preclinical models. Injection 
with purifi  ed, or infection with vaccinia virus–expressing 
BLLF1, has been shown to protect cottontop tamarins 
against a lethal, lymphomagenic EBV challenge (41, 42). 
Although BLLF1 had been identifi  ed as the dominant tar-
get of the neutralizing antibody response (43), protective 
immunity in these and other studies did not always corre-
late with the presence of virus-neutralizing antibodies, 
inferring a role for BLLF1-specifi  c cell-mediated   responses 
in disease protection (44). Th cell recognition of newly 
EBV-infected B cells after receptor-mediated cell   adhesion, 
penetration, and uncoating as described in the   present study 
may provide a mechanistic explanation for these fi  ndings. 
Thus, the targets of the EBV-specifi  c T helper cell response 
may not be limited to a small set of latent cycle proteins ex-
pressed in these tumors, but may also include   antigens 
transferred by virions.
MATERIALS AND METHODS
Generation and culture of LCL and miniLCL. Supernatant from the 
marmoset B cell line B95.8 was used as the source of wild-type virus to gen-
erate LCL from PBMCs using standard protocols. 1 μg/ml cyclosporin 
A was initially added to the cultures to inhibit T cell growth. MiniLCL were 
generated similarly, except that a mutant EBV strain unable to enter lytic 
replication was used (24). LCL and miniLCL were grown as suspension cul-
tures in LCL media consisting of RPMI 1640 supplemented with 10% FCS, 
1% nonessential amino acids, 1 mM sodium pyruvate, 2 mM l-glutamine, 
and 50 μg/ml gentamicin.
Protein expression and purifi  cation. Generation of recombinant bacu-
lovirus and protein expression in Sf9 cells has been described previously (45). 
Recombinant proteins were purifi  ed from cell lysates using Nickel-NTA 
(QIAGEN). Protein concentration was determined using Bradford reagent 
(Bio-Rad Laboratories). Purity and integrity of the proteins was verifi  ed by 
Coomassie staining and Western blot analysis using an anti-His6 monoclonal 
antibody (clone BMG-His-1; Roche).
Culture of T cell lines and clones. Whole blood was obtained from 
healthy laboratory members and HLA-typed using PCR-based methods. 
The HLA class II genotype of donor JM consists of the following: 
DRB1*0801, DRB1*1301, DRB3*0101, DQB1*0402, DQB1*0603, 
DPB1*0401, and DPB1*1301. EBV status of the donors was determined 
  serologically and by PCR analysis of throat wash samples. PBMCs were 
  isolated from heparinized venous blood by density gradient centrifugation 
on Ficoll-Paque (GE Healthcare). CD4+ cells from PBMCs were selected 
over MACS columns following the guidelines of the manufacturer (Miltenyi 
Biotec). To generate CD4+ T cell lines specifi  c for lytic antigens of EBV, 
106/ml autologous PBMCs in AIM-V medium (Invitrogen) were pulsed 
with recombinant proteins (500 ng/ml) for 24 h, washed, irradiated (40Gy), 
and used to stimulate an equal number of CD4+ T cells in 2 ml 
T cell media (RPMI 1640, 10% heat inactivated human serum, 2 mM 
l-  glutamine, 10 mM Hepes, and 50 μg/ml gentamicin) in 24-well plates. 
After 48 h, 10 U/ml recombinant IL-2 (Chiron) was added to the cultures. 
Limiting dilution cloning and expansion of the T cells was performed as 
  described previously (45).
Cytokine secretion by T cells. Specifi  city of T cells was tested by incu-
bating 105 target cells with 105 T cells in a fi  nal volume of 200 μl T cell 
  media. After 24 h of coculture, the cytokine content in the supernatant was 
measured by ELISA (R&D Systems). For mixing experiments, LCL and 
miniLCL were cocultured at a 1:1 ratio for diff  erent periods of time before 
addition of the T cells. Autologous DCs from donor JM were prepared as 
described previously (29). For peptide titration experiments, target cells were 
incubated with the various peptides at 37°C for 2 h, followed by extensive 
washing before the addition of T cells. BLLF1 antibody-blocking studies 
were performed by incubating virus supernatant with the anti-BLLF1 mono-
clonal antibody 72A1 (HB-168; American Type Culture Collection) or an 
isotype control antibody (fi  nal concentration 15 μg/ml) for 1 h at 37°C 
  before addition to target cells. For CD21 antibody blocking studies, 5 × 105 
miniLCL cells were incubated in 1 ml LCL medium with 5.6 μg/ml anti-
CD21 monoclonal antibody FE8 (Upstate Biotechnology) for 1 h and 
washed extensively before further use in antigen presentation studies. To in-
hibit lysosomal processing, chloroquine (ICN Biomedicals) and leupeptin 
(Sigma-Aldrich) were added to the target cells at a fi  nal concentration of 100 
μM and 200 μg/ml, respectively, together with the virus supernatant. After 
the incubation period, the inhibitors and excess virus were removed by 
washing, and the cells were fi  xed by treatment with 1% paraformaldehyde 
for 10 min at room temperature, followed by extensive washing before 
  addition of T cells. IFN-γ and perforin ELISPOT assays were performed as 
described previously (29, 46).
T cell cytotoxicity assay. Lysis of target cells by T cells was measured 
  essentially as described previously (47). In brief, target cells were labeled with 
BATDA reagent (PerkinElmer) for 15 min at 37°C. Subsequently, viable cells 
were washed and plated at 5,000 cells/100 μl per well in 96-well 
V-bottom plates. T cells were added at diff  erent eff  ector-to-target ratios and 
incubated for 3 h at 37°C. Subsequently, 40 μl of the culture supernatant from 
each well was mixed with 200 μl of europium solution and time-  resolved 
  fl  uorometry was measured after 15 min. Means of triplicates were calculated 
and the specifi  c lysis was calculated using the following formula: percentage 
specifi  c lysis = (mean release in the presence of T cells − mean minimum 
release)/(mean maximum release − mean minimum release) × 100.
Preparation of virus rich supernatant. Supernatant from B95.8 cells was 
fi  ltered through a 0.8-μm fi  lter and ultracentrifuged at 25,000 g for 3 h in a 
SW28 rotor (Beckman Coulter). The supernatant was removed and the vi-
rus-rich pellet was resuspended in 1/20 volume of the original culture super-
natant. The genomic copy number of this virus concentrate was determined 
by semi-quantitative real-time PCR using primers directed to the BALF5 
gene (48). For virus inactivation, the EBV supernatant was heated to 56°C 
for 1 h. Successful inactivation of virus infectivity was verifi  ed by the inabil-
ity of the heated virus supernatant to transform primary human B cells.
LCL and BL growth regression and LCL outgrowth inhibition 
assay. For growth regression assays, serial dilutions of cells were plated in JEM VOL. 203, April 17, 2006  1005
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96-well plates with or without 10,000 T cells/well in LCL media. The cul-
tures were refed weekly and the cultures were inspected for outgrowth of 
cells after 4 wk. T cell inhibition of LCL outgrowth was assessed by incubat-
ing CD19-positive cells from PBMCs for 4 h at 37°C with EBV supernatant 
(50 geq/cell). Subsequently, the cells were washed, and serial dilutions of the 
cells plated in 96-well round bottom plates together with T cells (10,000 
cells/well) in 200 μl of LCL media. Outgrowth of LCL was analyzed micro-
scopically and verifi  ed by CD19 staining.
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